XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome
Stéphanie Rigaud(Délégation Paris 5), Sylvain Latour(Institut des Maladies Génétiques Imagine), Patrick Revy(Inserm), Geneviève de Saint Basile(Inserm), Nathalie Lambert(Hôpital Necker-Enfants Malades), Pauline Soulas‐Sprauel(Inserm), Marie‐Claude Fondanèche(Délégation Paris 5), Frédéric Rieux‐Laucat(Inserm), Véronique Mateo(Délégation Paris 5), Benoit Pasquier(Délégation Paris 5), Lionel Galicier(Hôpital de la Timone), Françoise Le Deist(Centre National de la Recherche Scientifique), Alain Fischer(Inserm)
Cited by 701
Related Papers
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
|Science|2003|3.5k
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
|Science|2020|3.2k
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
|Science|2000|2.6k
A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency
|New England Journal of Medicine|2003|1.8k
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
|Journal of Clinical Investigation|2008|1.8k